Çocuklarda ilaç alerjileri

İlaç alerjisi, diğer alerjik hastalıklar ile karşılaştırıldığında en ağır klinik tabloya sebep olabilen dolayısı ile ihmalinde hayatı tehdit edebilen çok önemli bir durumdur. Kliniği hafif bir ürtikerden anafilaksiye kadar geniş bir aralıkta görülerek, diğer bütün alerjik hastalıkların bulgularını gösterebilir. Alerjik ilaç reaksiyonlarının önemli sonuçlarından biri ileride daha az etkili, daha pahalı veya daha toksik ilaçların kullanımına neden olmasıdır. Eksiksiz bir hikaye tedavi yaklaşımında çok önemlidir. Laboratuvar testlerinin ilaç alerjisi yönetimindeki rolü çok sınırlıdır. Tanıyı doğrulayıcı testler varsa, hastaların alerjik durumunu saptamak için uygulanmalıdır. Bu testler yoksa, önceki reaksiyona bağlı olarak aşamalı uyarı ve duyarsızlaşma uygulanabilir. Hasta ve hekimin eğitimi tedavinin önemli bir parçasıdır.

Drug allergies in children

Drug allergy when compared with other allergic diseases can be the cause of most serious reactions and in the absence of true diagnosis fatal outcome can be accepted. In clinical practice, a wide range of symptoms from mild urticaria to anaphylaxis can be seen so that it can mimic the symptoms of all allergic disease. One of the significant consequences of allergic drug reactions is causing the use of less effective, more expensive or more toxic drugs in the future. A thorough history is essential to the management of drug allergy. Laboratory testing has a very limited role in the management of drug allergy. Confirmatory tests, if avaliable, should be used to determine the allergic status of the patient. If these tests are not avaliable, depending on the type of clinical reaction previously demonstrated, a graded challenge or desensitization may be considered. Education of the patient and primary care physician is an important component of management.

PDF

___

1. World Health Organization. International drug monitoring: the role of the hospital. Geneva: The Organization, 1996.
2. Johansson SG, Bleber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-6.
3. Boguniewicz M, Leung DY. Atopic dermatitis. Middleton’s allergy: principles and practice: 7th Ed. China: Elsevier, 2009:1205-26.
4. Gomes ER, Demoly P. Epidemiology of hypersensivity drug reactions. Curr Opin Allergy Clin Immunol 2005:5:309-16.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998:279:1200-5.
6. Ghandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-64.
7. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in pediatric in/out patients: a systemic review and meta-analysis of prospective studies. Br J Clin Pharmaol 2001;52:77-83.
8. Orhan F, Karakaş T, Cakır M, et al Parental-reported drug allergy in 6-to 9-yr old urban school children. Pediatr Allergy Immunol 2008;19:82-5.
9. Fiwszenson-Albala F, Auzerie V, Mahhe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003;149:1018-22.
10. Coombs PR, Gell PG. Classification of allergic reactions responsible for clinical hypersensivity and disease. In: Gell PR (ed). Clinical aspects of ımmunology. Oxford: Oxford University Pres, 1968:575-96.
11. Pichler WJ. Delayed drug hypersensivity drug reactions. Ann Intern Med 2003;139:683-93.
12. Pichler WJ. Immune mechanism of drug hypersensivity. Immunol Allergy Clin North Am 2004;24:373-97.
13. Levine BB. Immunochemical mechanizms of drug allergy. Annu Rev Med 1966;17:23-38.
14. Pichler WJ. Pharmacological interaction of drugs with antigen-specific ımmune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002;2:301-5.
15. Haddi E, Charpin D, Tafforeau M, et al. Atopy and systemic reactions to drugs. Allergy 1990;45:236-9.
16. Sullivan TJ, Ong RJ, Gilliam LK. Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol 1989;83:270.
17. Hagan JB. Anaphylactoid and adverse reactions to radiocontrast agents. Immunol Clin North Am 2004;24:507-19.
18. Volchock GW. Clinical evaluation and management of drug hypersensivitiy. Immunol Clin North Am 2004;24:357-71.
19. McKenna JK, Lieferman KM. Dermatologic drug reactions. Immunol Clin North Am 2004;24:399-423.
20. Thong BU, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003;90:342-7.
21. Peyriere H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exists? Br J Dermatol 2006;155:422-8.
22. Allergic reactions to long-term benzathine penicillin prophylaxis fort he rheumatic fever. International Rheumatic Fever Study Group. Lancet 1991;337:1308-10.
23. Demoly P, Lebel B, Messaad D, et al. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 1999;54:500-6.
24. Rebelo Gomes E, Fonseca J, Araujo L, Demoly P. Drug allergy claims in children, from self-reporting to confirmed diagnosis. Clin Exp Allergy 2008;38:191-8.
25. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensivitiy: questionnaire. EAACI interest group on drug hypersensivity. Allergy 1999;54:999-1003.
26. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002;57 Suppl 72:37-40.
27. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensivity. Allergy 2002;57:45-51.
28. Ditto AM. Drug allergy. In: Grammer LC, Greenberg PA (eds). Patterson’s allergic diseases. Philadelphia: Lippincott Williams Wilkins, 2002:295-334.
29. Aberer W, Bircher A, Romano A, et al. European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensivity. Drug provocation testing in the diagnosis of drug hypersensivity reactions: general considerations. Allergy 2003;58:854-63.
30. Greenberg PA. Drug allergies. J Allergy Clin Immunol 2006;117:464-70.
31. Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy 2007;62:47-52.
32. Blanca M, Mayorga c, Torres MJ, et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicilin allergy. Allergy 2001;56:862-70.
33. Ebo DG, Sainte-Laudy J, Bridts CH, et al. Flow-assisted allergy diagnosis: current applications and future perspectives. Allergy 2006;61:1028-39.
34. Sanz ML, Gamboa PM, De Weck AL. Cellular tests in the diagnosis of drug hypersensivity. Curr Pharm Des 2008;14:803-8.
35. Lebel B, Messaad D, Kvedariene V, Rongier M, Bousquet J, Demoly P. Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reaction. Allergy 2001;56:688-92.
36. Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000;106:65-71.
37. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;36:1622-6.
38. Nyfeler B, Pichler WJ. The lymphocyte transformation test fort he diagnosis of drug allergy: sensivity and specificity. Clin Exp Allergy 1997;27:175-81.
39. Merk HF, Dorfmüller A, Sachs B, Baron JM. Delayed hypersensivity reactions. Which test exist? What is the sensivity and specificty of these tests? ACI Int 2002;14:194-8.
40. Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995;105(1 Suppl):95S-8S.
41. Friedmann PS, Lee MS, Friedmann AC, Barnetson RC. Mechanisms in cutaneous drug hypersensivity reactions. Clin Exp Allergy 2003;33:861-72.
42. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6:476-81.
43. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by subpotimal doses of antigen. Ann Allergy Asthma Immunol 2005;94:575-80.